Genmab — April 2019
-
Ny Janssen bispecific: https://clinicaltrials.gov/ct2/show/NCT03915379?term=JNJ-67571244&rank=1
-
"Two drugs stood out in boosting J&J’s results with better-than-expected sales. Anti-inflammatory treatment Stelara revenue increased to $1.41 billion from $1.06 billion, surpassing estimates of $1.36 billion. Multiple myeloma drug Darzalex increased to $629 million from $432 in the same time last year. Analysts had expected $627.7 million." cnbc https://www.cnbc.com/2019/04/16/johnson-johnson-q1-2019-earnings.html
-
-
Fra artikel linket til ovenfor (www.borsen.dk) : “Den peger samtidig på, at når Genmab i maj skal lægge sine kvartalstal på bordet, så vil det formentlig indeholde en opjustering af prognosen om at levere et driftsoverskud på 2 mia. kr., da forudsætningen for den spådom var en dollarkurs på 6 kr. I første kvartal har en dollar kostet nærmere 6,6 kr. ”
-
Jeg synes det er noget optimistisk at snakke brud igennem 1200, når kursen ligger meget nærmere 1100 ! Vi kan bare konstatere at nogle få store investorer bestemmer kursen suverænt. Det er bedre at Genmab guider lavere og så opjusterer henover året.....det vil give nogle flere positive overraskelser.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind